Innovative Bahraini Deal Inked For Sickle Cell Therapy
This article was originally published in Scrip
Executive Summary
As part of a clinical collaboration agreement between the Arabian Gulf University in Bahrain and the Swedish biotech, Dilaforette AB announced Feb. 16, the Middle East University has shouldered some of the risk of developing the company's potential sickle cell therapy, sevuparin.